Nymox Reports 2009 Financial Results
Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug
New Peer-Reviewed Paper in Expert Opinion on Investigational Drugs
Nymox Announces New $15 Million Equity Financing Commitment
Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company’s BPH Drug NX-1207
Nymox Reports Third Quarter 2009 Financial Results
Nymox's NX-1207 To Be Clinically Tested for Prostate Cancer
Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH
Nymox's NX-1207 Shows Major Effect on Liver Cancer
Nymox Reports Second Quarter 2009 Financial Results
Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPH
Nymox Reports First Quarter 2009 Financial Results
Nymox Announces Start of Second Phase 3 Trial for NX-1207 for BPH
Nymox Reports Initiation of Phase 3 Trials for NX-1207 for BPH
Nymox Reports 2008 Financial Results
Nymox Announces New Positive Results at 5 Years After Single Treatment in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug
Nymox Releases Positive New Clinical Trial Data on Durability of Response Rates to Company’s BPH Drug NX-1207
Third Hand Smoke Recognized as Health Hazard
Nymox Announces $15 Million Equity Financing Commitment
Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug
Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement
Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 Investigational Drug for BPH
Nymox Reports Third Quarter 2008 Financial Results
Nymox Reports Positive New Results in 59 Week Study of Drug for Enlarged Prostate
Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Monterey
Powerful New Evidence Shows Statin Drugs Reduce Risk of Alzheimer’s Disease
Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday
Nymox Nears Completion of New One Year U.S. Study of BPH Drug
Statins Reduce Risk of Alzheimer’s Disease According to New Long-Term Prospective Study
Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
Nymox Updates NX-1207 Product Development Activities
Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Chicago
Clinical Results for Nymox BPH Drug NX-1207 to Be Presented at American Urological Association Meeting in Chicago on September 25
Nymox NX-1207 Data Presented at American Urological Association Meetings in San Diego and Santa Ana Pueblo, New Mexico
Clinical Trial Results for NX-1207 to be Presented at Second AUA Meeting in San Diego on September 18
Clinical Trial Investigators To Present New Data Next Week on Nymox’s NX-1207 For Benign Prostatic Hyperplasia
Nymox Reports Second Quarter 2008 Financial Results
New Long-Term Prospective Study of Statin Drugs Confirms Utility To Reduce Risk of Dementia and Memory Loss
New Data on Nymox BPH Drug To Be Presented at American Urological Association Meeting in Monterey October 26-30
Nymox’s NicAlert™ Gains Acceptance in Clinical Trials and Research Studies
Almost 50% of Americans Exposed to Second-Hand Smoke According to New Report From Centers for Disease Control
BPH: A Major Challenge for Men’s Healthcare - Nymox's Innovative Treatment for BPH Enters Phase 3
Independent Clinical Trial Investigators To Present New Data on Nymox’s NX-1207 Drug in Development For Benign Prostatic Hyperplasia
Nymox Starts Phase 3 Program for NX-1207
Nymox Announces New Clinical Trial Data Presentation on BPH Drug at Upcoming American Urological Association Meeting
Nymox Reports Significant Long-Term Improvement in BPH Symptoms After NX-1207 Treatment in New Multi-Center U.S. Study
Independent Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting in Chicago September 25
Nymox Reports First Quarter 2008 Financial Results
Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion
Brief Exposure to Second-Hand Smoke Bad for Health According to New Study
Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
New Peer Review Publications Support Nymox Saliva Smoking Test
Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting
Nymox Nears Completion of Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox Releases Positive New Clinical Trial Data on Response Rates to Company’s Prostate Drug NX-1207
Nymox Reports 2007 Financial Results
Nymox Releases Further Results from Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox’s NX-1207 Offers a New and Attractive Approach to the Treatment of Benign Prostatic Hyperplasia
Two New Published Studies Emphasize The Need for Testing Tobacco Use and Second-Hand Smoke Exposure
Nymox Pharmaceutical to Present at the Growth and Value Investor Conference
Nymox Announces Positive Results from New Multi-Center U.S. Study of NX-1207 For BPH
Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH
Nymox Announces $15 Million Equity Financing Commitment
Expert Review of Molecular Diagnostics Publishes Positive Report on Nymox Alzheimer Test
Nymox Reports Update on NX-1207 Study Results, Marketing Plans and Activities
Nymox Announces Positive Results in New 2 Year Blinded, Placebo Controlled Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox Reports Completion of Large New 2 Year Follow-up Study of
Nymox Reports Third Quarter Financial Results for 2007
Nymox Announces Clinical Study Presentation on New BPH Drug at Upcoming American Urological Association Meeting
Nymox Announces New BPH Drug Long Term Follow-up Study Clinical Data Presentation October 20 at American Urological
Nymox Announces BPH Drug Clinical Data Presentation September 28 at American Urological Association Meeting
Nymox Saliva Test Strongly Supported By New Independent Study Data Published in Cancer Epidemiology Biomarkers & Prevention
Nymox BPH Drug Data Presentation September 8 at American Urological Association Meeting
Major New Study Supports Validity of Statin Drugs Potential For Alzheimer’s Treatment
Nymox Announces New Clinical Data From BPH Drug Trials To Be Presented at Upcoming U.S. Urology Meeting
Nymox Reports Second Quarter Financial Results for 2007
WallStreet Research Releases Buy Recommendation for Nymox Pharmaceutical Corporation
Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting
Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
NicAlert™ Study in Children to be Presented at American Thoracic Society Conference in San Francisco
Nymox Reports First Quarter 2007 Financial Results
Nymox Announces New Positive Results from 3 ˝ Year Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
Nymox Announces Positive Results from Newly Completed Long-Term Study of NX-1207 for Benign Prostatic Hyperplasia
Nymox Reports 2006 Financial Results
Nymox Reports Completion of New Long-term Study of NX-1207 for BPH
Nymox Reports Update on Prostate Drug Licensing Negotiations
Journal of Clinical Laboratory Analysis Publishes Positive New Data Bolstering Nymox’s AlzheimAlert™ Urine Test for Alzheimer’s Disease
Nymox Protein Biomarker for Alzheimer's is Years Ahead of Competition
Nymox NXC-4720 Reduces E. Coli Contamination By 99%
Nymox Announces $13 Million Equity Financing
Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good for Alzheimer's Disease
Nymox Pursuing New Approaches to an Old Disease
Nymox Product a Tool for Smoking Cessation Efforts
Nymox Reports Third Quarter 2006 Financial Results
Statin Drugs Gain Traction as Potential Treatment for Alzheimer’s Disease
Nymox Pharmaceutical to Present at the 29th Annual Westergaard SmallCap Conference
Nymox Pursuing Plans for Marketing Partnerships for Its NX-1207 BPH Drug
Demand for Enlarged Prostate Treatments Expected to Rise Sharply
Journal of the American Medical Directors Association Publishes Positive Independent National Study of Nymox's AlzheimAlert™ Urine Test For Alzheimer's Disease
Nymox Targets E. Coli Food Contamination with Innovative New Products
Nymox Pharmaceutical to Present at the Noble Financial Small Cap Conference
Nymox Announces Positive Results from Completed Phase 2 BPH Drug Trial
Nymox Products Profiled in New Reports
Nymox AlzheimAlert™ Independent Clinical Trial Data To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology
New Lancet Study: Second Hand Smoke Increases Heart Attack Risk
Nymox Reports Second Quarter 2006 Financial Results
Second Hand Smoke Exposure Associated With Pediatric Anesthesia-Related Airway Complications
Multiple Newly Published U.S. and European Peer-Review Studies Support Statin Drug Potential Therapeutic Use in Alzheimer's Disease
Value of Nymox's NicAlert™ For Monitoring Pregnant Women Confirmed by New Independent Study in Alaska
New Studies Bolster Potential of Statin Drugs for the Treatment of Alzheimer's Disease
Nymox NicAlert™ Product to be Used in Large Collaboration For Smoking Cessation in U.K.
Three Independent Analyst Reports Give Nymox “Buy” Recommendations
New Study Proves Second Hand Smoke Makes Allergies Worse
New Study Finds that Statin Drugs Protect Against Cognitive Decline
New Buy Recommendation for Nymox in Report From WallStreet Research
U.S. Survey: Enlarged Prostate Problems Pose a Major Challenge to Health Care Systems
Nymox “Buy” Recommendations in Two Independent Analyst Reports
New Nymox Product Study Data to be Presented at 13th World Conference on Tobacco or Health
Surgeon General Declares Second-Hand Smoke Indisputable and Alarming Public Health Hazard
Nymox Reports Update on Multi-Center Trial of Benign Prostatic Hyperplasia Drug
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease
Nymox Signs New Sales and Marketing Agreement for Alzheimer's Test with Kyung Min Meditech Co. Ltd. In Korea
Nymox Reports Completion of NX-1207 Dosing in Current Multi-Center BPH Drug Trial
Nymox Pharmaceutical Corporation Holds Annual Shareholders Meeting
New Study Links Second-Hand Smoke to Allergy Risk for Infants
Updated Analyst Reports Give Nymox “Buy” Recommendation
Nymox AlzheimAlert™ Findings To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology
Nymox Reports Positive New Efficacy Data for Benign Prostatic Hyperplasia Drug
Nymox Reports First Quarter 2006 Financial Results
New Study of Infants Highlights Second Hand Smoke Risk
Nymox AlzheimAlert™ Findings To Be Presented at the 4th Bologna International Meeting on Affective, Behavioral and Cognitive Disorders in the Elderly
Nymox Gains Regulatory Milestone in Europe For Saliva Test
Nymox Signs Italian Distribution Deal for NicAlert™ with Alifax S.p.A.
Nymox's Second-Hand Smoke Test Newly Launched in the U.K.
Nymox AlzheimAlert™ Findings To Be Presented at Annual Meeting of the American Psychiatric Association
Long Term Statin Drug Use Safe According to Safety Task Force
Nymox “Buy” Recommendations in Three Independent Analyst Reports
Nymox Reports Latest Interim Review of Safety Data for Benign Prostatic Hyperplasia Drug
Nymox to Present at Dutton Associates' “Recognizing Opportunity” SmallCap Conference in San Francisco March 28
Nymox Reports 2005 Financial Results; Product Sales Increase by 32%
Nymox AlzheimAlert™ Findings To Be Presented at National Meeting in Dallas
Nymox Expands Its Patent Portfolio Foundation For Product Development
Nymox Study Data to be Presented at World Conference on Tobacco in Washington
Nymox NXC-4720 Late Stage Product Targets E. Coli Food Contamination
Statin Drug Potential for Alzheimer's Disease Gains Ground with Recent Studies
Public Awareness of Health Risks from Second-Hand Smoke Exposure Grows Worldwide
Nymox “Buy” Recommendations in Three Independent Analyst Reports
Nymox Reports on Company's New Interim Review of Safety Data for Benign Prostatic Hyperplasia Drug
What is Good for the Heart is Good for the Brain According to NIH Report
Nymox Saliva Test Data to be Presented at National Meeting This Week
Nymox AlzheimAlert™ Findings To Be Presented at Annual Meeting of the American Psychiatric Association
Nymox's Alzheimer Test to be Provided in U.K. by Lab21
Statin Drug Potential for Alzheimer's Disease Bolstered by Recent Studies
Nymox's Alzheimer Drug Programs Generate Several Novel Product Developments
Nymox Recommended in Three Recent Independent Analyst Reports
Nymox NicAlert™ Saliva Data to be Presented at International Meeting of Nicotine and Tobacco Experts
Nymox Obtains CE Mark for NicAlert™; Product Now Available in Europe
Nymox NX-1207 Pivotal Trial Gets Positive Efficacy and Safety Recommendation from Independent Data Monitoring Committee
Nymox AlzheimAlert™ Findings To Be Presented at National Meeting Annual Symposium of the American Medical Directors Association
Studies Show Nymox's AlzheimAlert™ Test Useful in Earliest Stage of Alzheimer's Disease
E. Coli Contamination a World-Wide Public Health Threat
Nymox Reports Completed Successful Studies of Saliva Test
Nymox Signs New U.K. Deal for NicAlert™ Product
Nymox Provides Update on Progress of the Company's Current Drug Trial of NX-1207 for Benign Prostatic Hyperplasia
WallStreet Research Updates Coverage of Nymox Pharmaceutical Corporation Shares with Speculative Buy Recommendation at www.WallStreetResearch.org
Statin Drugs May Help Reduce Alzheimer's Disease Risk in Many Ways, According to Expert
Nymox Signs U.K. Deal for TobacAlert™ Second-Hand Smoke Test
Nymox Receives Buy Recommendation with New Update by Cohen Independent Research Group
Nymox Reports Updated Interim Safety Results in Pivotal Trial of New Drug For Benign Prostatic Hyperplasia
New Lancet Article Points to Role for Cholesterol and Statin Drugs in Alzheimer's Disease
CDC Researchers Find New Use for Nymox's NicAlert™ Product
New Cardiovascular Studies Show Harm From Very Brief Exposure to Second Hand Smoke
New Study Finds Additional Evidence that Statin Drugs May Help Slow Mental Decline in the Elderly
Statins May Slow the Effects of Alzheimer's Disease According to New Study
Nymox Reports Third Quarter 2005 Financial Results
Medical Publication Highlights Positive Advances in Clinical Studies of Preventive Effects of Statin Drugs in Alzheimer's Disease
Nymox Product Recommended in Today's London Daily Mirror
New Study Finds that Second-Hand Smoke Exposure Doubles Lung Cancer Risk
Nymox Files Further Proposals with FDA about Alzheimer Test Kit
E. Coli Food Contamination of Beef a Threat World-Wide
Nymox Announces $13 Million Equity Financing
Nymox Smoking Test Products Receive Wide Media Coverage
Nymox Signs New Marketing and Distribution Deal for NicAlert™ Test in Spain
Nymox Reports Second Positive Interim Safety Results in Pivotal Trial of New Drug For Benign Prostatic Hyperplasia
Nymox Adds European Sales Agreements For Company's Proprietary Unique AlzheimAlert™ Test
Routine Screening for Second-Hand Smoke Exposure Recommended
Nymox NXC-4720 Product in Late Stage Development for E. Coli O157:H7 Contamination
Potential of Statins to Treat or Prevent Alzheimer's Disease Widely Recognized
Nymox Continues to Successfully Expand Extensive Patent Portfolio
Nymox NicAlert™ Featured in Nevada Tobacco Free Babies Project Presentation
New Published Articles Support Mechanisms for Potential Use of Statins to Treat Alzheimer's Disease
Update on Pivotal Trial of Nymox's NX-1207 For Benign Prostatic Hyperplasia
Lancet Article Features Potential Use of Statins to Treat Alzheimer's Disease
Nymox Signs Marketing Agreement With Brainpharma S. L. For AlzheimAlert™ Kit to Be Sold in Spain
Second-Hand Smoke Kills as Many Women as Active Smoking in China According to New Study
New Study Finds Early Life Second-Hand Smoke Exposure Can Produce Life-Long Respiratory Problems
Second-Hand Smoke Costs $10 Billion A Year According to Insurance Study
Second-Hand Smoke Takes its Toll Later in Life
Nymox Reports Second Quarter 2005 Financial Results; Product Sales Increased by 63% over Second Quarter 2004
Nymox NicAlert™ Will be Used in Nevada Tobacco Free Babies Program
Positive Interim Safety Results of Pivotal Trial of Nymox's NX-1207 For Benign Prostatic Hyperplasia
Tobacco Smoke Exposure for Teens Linked to Obesity and Higher Risk of Cardiovascular Disease and Diabetes
Second-Hand Smoke Exposure During Pregnancy Puts Fetus at Risk According to New Study
Nymox Expands Its Issued Patent Position for E. Coli Treatments
New Coverage of Nymox Initiated by Cohen Independent Research Group
FDA Panel Votes 5-2 Against Kit Form of NTP Test
Evidence and Acceptance Grows For Taking Statin Drugs to Treat Dementia
Nymox Moves Forward With Global Marketing Agreements For Company's Proprietary AlzheimAlert™ Test
Nymox NX-1207 For Benign Prostatic Hyperplasia Shows Promise For Common Problem
Nymox Signs Marketing and Distribution Deal for AlzheimAlert™ Kit in Greece
Exposure to Mother's Smoke Increases Risk of Asthma in Adults According to New Study
Nymox Reports Positive New Data for BPH Drug
Newly Published Studies Show Danger of Second Hand Smoke
FDA Advisory Panel Meeting for Nymox PMA Application Expected in July 2005
Nymox and InnerLink Sign Agreement to Promote Nymox Tobacco Exposure Products
Another Large New Published Study Shows that Taking a Statin Drug Reduces the Risk of Dementia
Nymox Reports First Quarter 2005 Financial Results
Standard & Poor's Stock Reports Gives Nymox “Bullish” Rating
New Study Finds Evidence that Taking a Statin Drug Can Help Treat Alzheimer's Disease
Statin Drugs Offer Positive New Pharmaceutical Approach to Alzheimer's Disease Treatment and Prevention
Second-Hand Smoke Exposure a Key Topic at National Conference on Tobacco or Health
Nymox Product Recommended in Today's N.Y. Daily News
Nymox PMA Slated for FDA Advisory Panel Meeting
Nymox Signs Marketing and Distribution Deal for Alzheimer's Disease Test with KlinLab in Czech Republic
Nymox NicAlert™ Successfully Used as Clinical Tool for Expectant Mothers in Nevada
Deadly E. Coli Bacteria Remains an Important Threat to U.S. Health According to New Study
Newly Published Study Shows Growing Medical Acceptance of Statin Drug Usefulness in Treatment of Dementia
New Medicare Decision to Cover Smoking Cessation Good News for Nymox
Nymox Makes Major Progress in Global Marketing of Company's Proprietary Alzheimer Test
Nymox Drug For Benign Prostatic Hyperplasia Holds Promise For Highly Prevalent Problem
Two New Studies Document Dangers of Second Hand Smoke and Fetal Exposure to Maternal Smoking
European Studies Show That Nymox's NicAlert™ Product Improves Smoking Cessation
Nymox Reports 2004 Financial Results
New Reports and Studies Highlight Importance of Alzheimer's Disease Diagnosis
Breast Cancer Linked to Second Hand Smoke in New Report
Nymox NicAlert™ Product Can Help Smoking Cessation
Insulin Abnormalities Linked to Alzheimer's Disease by Researchers
Effective Measures Needed to Reduce Tobacco's Deadly Toll
Studies Show that Nymox NXC-4720 Product Can Substantially Reduce E. Coli Meat Contamination
Nymox Expands Large Patent Portfolio
Nymox Signs Italian Distribution Deal for Alzheimer's Disease Test with Alifax S.p.A.
Nymox's Alzheimer Urine Test Now Available as Kit in Europe
Childhood Exposure to Second Hand Smoke Increases Lung Cancer Risk for Adults According to New Study
Second Hand Smoke Adversely Affects Children's Reading Scores, Math Skills and Reasoning Abilities
Nymox Files Data with FDA for Alzheimer Urine Test
Nymox Pharmaceutical Rated “Bullish” by Standard & Poor's Stock Reports
Alzheimer's Disease Identified as a Priority for Europe in World Health Organization Study
Nymox Reports Third Quarter 2004 Financial Results
Taking Statin Slowed Progression of Alzheimer's Disease According to New Study
Nymox Obtains CE Mark for AlzheimAlert™ Test Kit; Product Now Available in Europe
Nymox Files PMA Amendment with FDA for Alzheimer Urine Test
Statin Drugs and Mechanism for Alzheimer's Explored in Large Group of New Scientific Studies
Nymox Issued U.S. Patent for Saliva Cholesterol Test
Nymox TobacAlert™ To Be Available at CVS Pharmacies Across the U.S.
Nymox Announces $13 Million Equity Financing
Nymox Signs Licensing Agreement with Health Canada
Nymox's TobacAlert™: A Simple, Cost-Effective Way of Measuring Second Hand Smoke
Nymox Makes Steady Progress With Alzheimer's Products
Nymox Develops New Methods of Treating Deadly E. Coli Food Contamination
Nymox Files 6K Re Insider Stock Purchases
Statin Drugs For Alzheimer's Recognized as Emerging Indication
Nymox Successfully Expands Growing Patented Product Pipeline
Nymox has Good News for National Prostate Health Month
Statins Offer Hope for Alzheimer's Prevention
Nymox Announces Positive One Year Prostate Drug Trial Results
Nymox Reports Second Quarter 2004 Financial Results
Nymox Announces Positive Settlements of Outstanding Litigation
Nymox Advances Site Selection for New Prostate Trial
Capital Growth Financial Reiterates “Buy” Recommendation of Nymox
Nymox Reports Current Status of NTP Kit PMA
Nymox Develops Treatment of Deadly E. Coli Food Contamination
Nymox Releases Further Positive Data on U.S. Clinical Trials of NX-1207 in Men with
Statin Drugs Attract Wide Attention For Alzheimer's Prevention
Clinical Study Shows New Use for Nymox AlzheimAlert™ Test
New Drug Trial Protocol Approved for Nymox Prostate Drug
Nymox Rated “Bullish” by Standard & Poor's Stock Reports
Nymox Pursuing New Approaches to Fighting Alzheimer's Disease
Nymox's Tobacco Exposure Products Pass the Test in Australia
Nymox AD Protein Marker Linked to New Cell Death Mechanism in Alzheimer's Disease
Nymox Releases Positive Data on U.S. Clinical Trials of NX-1207 in Men with Benign Prostatic Hyperplasia -BPH-
Nymox Gives Update Before Company's Annual General Meeting
Nymox Reports First Quarter 2004 Financial Results
CGF Securities Reiterates “Buy” Recommendation of Nymox with $9.00 Price Target
Another Distinct Major New Study Confirms the Benefits of Statins in Reducing Risk of Alzheimer's Disease
Large New Study Supports Statins For Alzheimer's Disease
Nymox Alzheimer Urine Test Premarket Approval -PMA- Application Suitable for Filing
Spheron Discovery Leads Nymox Alzheimer Developments
Nymox Gains U.S. Patent For Saliva Cholesterol Test
Future Value of Statin Drugs for Alzheimer's Quickly Growing According to Nymox
Large New Study Shows Statins Boost Cognition in the Elderly
Statin Drugs Reduce Alzheimer's Risk According to Studies
Nymox Reports 2003 Financial Results
Nymox Reports Progress in NXC-4720 E. Coli Product
Nymox Alzheimer Biomarker Bolstered by New Findings in Journal of Alzheimer's Disease
Nymox Shares Rated “Buy” in New Analyst Report
New Study Finds a 39% Reduction in Alzheimer's Disease in Patients Taking Statin Drugs
Nymox Files Premarket Approval Application with FDA for Alzheimer Urine Test
Nymox's TobacAlert™ Product Attracts World-Wide Attention
Drugs Reducing Cholesterol May Lower Risk of Alzheimer's Disease According to Recent Studies
Six Independent Analyst Reports Recommend Nymox
New Trial Results of Nymox NX-1207 Show Significant Clinical Improvement in Men with Benign Prostatic Hyperplasia –BPH–
Nymox Rated “Buy” in New Analyst Report From TNI Securities
New Study Shows Importance of Nymox AlzheimAlert™ Protein to Alzheimer's Disease
Five Independent Analyst Reports Recommend Nymox
New Study Confirms Nymox NXC-4720 Product Effective Against E. Coli
Nymox Pharmaceutical Rated “Bullish” by Standard & Poor's Stock Reports
Four Independent Analyst Reports Recommend Nymox
Nymox Rated “Buy” in Initial Coverage Report by CGF Securities
Nymox Shares Rated a Buy in Analyst Report
Nymox Reports Third Quarter Results
Nymox Will File Premarket Approval Application – PMA – with FDA for Alzheimer Urine Test
Wallstreet Research Updates Coverage of Nymox Pharmaceutical Corporation
Three Current Analyst Reports Recommend Nymox
Nymox Pharmaceutical Corporation: Second-Hand Smoke Exposure High On The Public Agenda Across The U.S.
Nymox Advances in the Treatment of Deadly E. coli Food Contamination
Nymox Shares Rated a Buy in Analyst Report
Nymox Adds New Drug Candidate for Neurodegenerative Disease to Product Pipeline
Early and Accurate Diagnosis of Alzheimer's Disease High Priority for the Health Care System According to Nymox
New Clinical Studies Show High Accuracy of Nymox's TobacAlert™
Statin Drugs Offer Hope for Meeting the Challenge of Alzheimer's Disease
New Clinical Data Strengthens Nymox AlzheimAlert™ Product
New Spheron Discovery Bolsters Nymox's Alzheimer Therapeutic Pipeline
Smoking Cessation Programs Reduce Healthcare Costs for Employers
Nymox Targets AlzheimAlert™ Product for the Global Market
Nymox Management Announces Up to Four New Investigational Drugs
Nymox Reports New Positive Studies of AlzheimAlert™ Product
Nymox New TobacAlert™ Product Now Available at CVS Pharmacies
Nymox Introduces New TobacAlert™ Product
Nymox Announces $12 Million Additional Financing
New Analyst Report Recommends Nymox Shares
Recent Surveys Show Nymox Products Widely Featured on Television in U.S. and Abroad
Alzheimer's Disease Rising Prevalence Will Challenge Health Care System
Nymox Reports Positive NXC-4720 E. Coli Product Data
Nymox Reports Positive Data on AlzheimAlert™ Product
Nymox Records Positive Interim Results in Phase I Testing of NX-1207 Prostate Drug
Nymox Reports Second Quarter Results
Nymox Announces E. Coli Collaboration for Research with Health Canada
New Survey Results Show That Few Young Women Smokers Able to Quit
Nymox Brings Unique Approach to Alzheimer's Disease
Antimicrobial Products Needed to Combat E. Coli Contamination
Recent Studies Support Potential for Statin Drug Use in Alzheimer's Disease
Nymox Recommended in Three Recent Independent Analyst Reports
Statin Drugs and Their Promise Against Alzheimer's Disease Featured in Cover Story of Newsweek Magazine
Employee Benefit Programs in U.S. Increase Coverage of Smoking Cessation Programs
Beef Recall Highlights Need for E. Coli Treatment
Nymox Products Widely Featured on U.S. Television
Dutton & Associates Reiterate "Buy" Recommendation for Nymox Pharmaceutical Corporation
Alzheimer's Disease Highlighted as Potential New Indication for Statin Drugs
American Respiratory Alliance Will Use Nymox's NicAlert™ as its Official Test Agent in Smoking Cessation Programs
Nymox Pharmaceutical Corporation Recommended in Three Current Independent Analyst Reports
Nymox Rated "Speculative Buy" By New WallStreet Research Report
Nymox Management Projection of Up to Four New INDs in the Next 12 Months
Nymox Pharmaceutical Corporation Recommended in Two Independent Analyst Reports
Nymox Rated "Buy" By Kareg Corporation Analyst
Nymox Innovative Alzheimer Drug Programs Report Progress
Nymox Reports Progress in Oncology Collaboration With Brown University Medical Researchers
Nymox NicAlert™ Product Used Successfully in European Broadcast TV Smoking Cessation Program
Nymox NicAlert™ Product Used to Help High School Students Quit Smoking
Nymox Reports Positive Alzheimer Drug Candidate Research
Task Force Report Highlights Need for Accurate Diagnosis of Alzheimer's Disease
Smoking During Pregnancy Affects Newborn Behavior According to New Study
European Clinical Trial Shows Nymox NicAlert™ Product Can Help Smokers Quit
Nymox Reports NXC-4720 E. Coli Product Update
Nymox Reports Positive New Data on AlzheimAlert™ Product
Recent Studies Support Statin Drug Treatment Potential in Alzheimer's Disease
Nymox Scientists Uncover Major New Molecular Clue to Alzheimer's Disease
Swiss Study Shows Nymox's NicAlert™ Helps in Smoking Cessation Therapy
Nymox's NicAlert™ Used in Conjunction With Nicotine Replacement Therapy Results in Higher Smoking Cessation Success Rates
Alzheimer's Disease Poses Major Challenge to Health Care System According to Experts
Fourth Manhattan Alzheimer's Disease Conference, sponsored by Nymox Pharmaceutical Corp., to be Held in New York on May 27
Nymox "Buy" Recommendation from Dutton & Associates
Nymox Reports First Quarter Results
Nymox AlzheimAlert™ Urine Test Useful to Monitor Alzheimer Treatment According to New Studies
Nymox's NicAlert™ Checks for Winners in Quit Smoking Contest
New Study Supports Statin Drugs Potential in Alzheimer Patients
Availability of AD Treatments Increases the Value of Nymox's AlzheimAlert™
Nymox E. Coli Treatment Targets a Pressing Need
Nymox Appoints New Senior Manager for Global Sales and Marketing
Fourth Manhattan Alzheimer's Disease Conference on May 27 Sponsored by Nymox Will Feature World Class Assembly of Speakers and Panelists
Nymox's NicAlert™ Can Detect Second-Hand Smoke Exposure in the Home
Nymox Reports Positive Results for NXC-4720 E. Coli Treatment
Statin Drug Treatment for Alzheimer's Supported by New Findings
Nymox Reports 2002 Financial Results
Dutton and Associates Initiates Coverage of Nymox With a "Buy" Recommendation
Nymox's NicAlert™: A Valuable Tool for Smoking Cessation Programs
Nymox Announces New Successes with Diagnostic Platform
New Second Hand Smoke Trial Results Confirm Usefulness and Accuracy of Nymox's NicAlert™
Nymox Announces $5 Million Additional Financing
Excellent Results for Nymox's NicAlert™ Presented at National Meeting
Nymox Begins Phase I Human Studies for NX-1207 Prostate Treatment
Nymox Develops New AlzheimAlert™ Test Kit for Overseas Markets
Statin Drug Treatment Potential For Alzheimer's Bolstered By New Studies
Nymox's NicAlert™ Can Determine Smoke Exposure in High Risk Patients in the Clinic
Nymox's NicAlert™ Successfully Used By High School Students in Switzerland
Nymox Announces Private Placement
New Public Health Importance For Nymox's NicAlert™
Nymox Rated "Buy" In New Analyst Report from WallStreet Research
Nymox's AlzheimAlert™ Can Help in the Early Diagnosis of Alzheimer's Disease
Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports
New Markets Open for Nymox's NicAlert™
Nymox's NicAlert™ Helps Physicians Determine Tobacco Smoke Exposure and Smoking Status of Their Patients
Nymox U.S. Patent Issued For Statin Drugs For Alzheimer's Disease
Nymox Enters into New Sales Agreement for NicAlert™ in Japan
FDA Clears Nymox's NicAlert™
Important New Publication Adds Prestige to Nymox Product
New Published Independent Study Finds Nymox Product to Be a Rapid and Cost-Effective Measure of Smoking Status
New Progress With Nymox's AlzheimAlert™ Product
Nymox Successfully Expands Growing Product Pipeline
Nymox Reports Alzheimer Drug Progress
Nymox Announces Private Placement
Nymox NicAlert™ Used in Major Lung Center in Zurich, Switzerland
Nymox NicAlert™ Used in National Stop-Smoking Campaign in Switzerland
New Nymox AlzheimAlert™ Study Begins in Phoenix
Nymox Announces New Marketing Initiatives With Health4u in Switzerland
Nymox Begins New NicAlert™ Study For Second-Hand Smoke
Nymox Leads with Innovative Alzheimer's Disease Programs
New Nymox AlzheimAlert™ Study at State University of New York
New Nymox Second-Hand Smoke Study Begins for NicAlert™
Second-Hand Smoke Implicated in Heart Disease and Stroke
Nymox NicAlert™ Test Valuable In Employee Tobacco Cessation Programs
Nymox Announces Private Placement
New Evidence Supports the Use of Statins for the Prevention and Treatment of Alzheimer's Disease
Nymox's AlzheimAlert™ To Be Presented at the Annual Meeting of the American Association for Clinical Chemistry
Nymox Gains U.S. Patent for Use of Statins for Prevention and Treatment of Alzheimer's Disease
Significant New Evidence Links Nymox's AlzheimAlert™ Protein to Alzheimer's Disease Process
Nymox Pharmaceutical Corporation Featured in The Wall Street Transcript
Nymox Files Investigational New Drug, IND, Application with FDA for Prostate Drug Candidate NX-1207
World Health Organization Links Second Hand Smoke to Cancer
Nymox Announces Progress with Drug Candidate for Alzheimer Treatment
Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports
Nymox Plans to File Investigational New Drug-IND-Application with FDA for Prostate Drug Candidate NX1207
Nymox Submits 510k Application to FDA For NicAlert™ Test
New Study on Teen Smoking Shows How Easily Smoking Leads to Nicotine Dependence
Nymox Presents Positive AlzheimAlert™ Results at Annual Meeting of American Geriatrics Society
Nymox Pharmaceutical Shares Upgraded to "Buy" Recommendation by WallStreet Research
Nymox's NicAlert™ Can Help Smokers Quit
Successful New Clinical Study of Nymox's AlzheimAlert™ Test Reported in Alzheimer's Reports
New Positive Results for Nymox's AlzheimAlert to be Presented at National Meeting
Nymox Obtains Cancer Marker Licensing Agreement from Massachusetts General Hospital
Nymox More Than Doubles 2001 Revenues and Announces Significant Improvement in Results
Nymox Announces New Cancer Therapeutic Program with Brown University
Nymox's NicAlert Potential Aid in Second-Hand Smoke Child Custody Cases
Nymox Announces Private Placement
Medicare's Decision to Cover Treatment for Alzheimer's Disease Will Positively Impact on Nymox's AlzheimAlert™
Nymox AlzheimAlert™ Featured on Good Housekeeping Medical Report Broadcast
Nymox Reports Continued Progress with Prostate Drug Candidate NX1207
Nymox Selected For BusinessWeek Equity Investor's Micro-Cap Review
Nymox's AlzheimAlert™ Test to be Used in Tufts University Study on Alzheimer's Disease
New Study Shows Nymox NicAlert™ Product Detects Second-Hand Smoke in Children
Nymox Develops New Alzheimer Drug Candidate
Nymox Announces Private Placement
Nymox Adds New Online Marketing Initiatives
Large National Study Supports Nymox's Emerging AlzheimAlert Diagnostic Technology
Nymox Announces New Research and Licensing Agreement With Brown University
Nymox Pharmaceutical Shares Recommended by WallStreet Research at www.WallStreetResearch.org
Nymox AlzheimAlert™ Story to be Internationally Televised in 200 Cities and 127 Countries Worldwide
Online Publication of Successful Clinical Study of Nymox's AlzheimAlert™ Test
Nymox Management and Directors to Purchase Up to One Million Nymox Shares
Nymox's AlzheimAlert™ Test Featured as Useful Biomarker for Alzheimer's Disease in Current Issue of Clinical Laboratory International
Nymox Alzheimer's Research Leads to Promising Prostate Drugs
Company Plans to File Investigational New Drug Application for Benign Prostatic Hyperplasia in 2002
Nymox AlzheimAlert™ Urine Test Shows Promise to Monitor Alzheimer Treatment and Progression According to New Study
Third Manhattan Alzheimer's Disease Conference, Sponsored by Nymox Pharmaceutical Corp., to be Held in New York on November 28
Nymox's AlzheimAlert™ To Be Presented at the Annual Meeting of the Society for Neuroscience
Nymox Technology Highlighted in Science Magazine
Nymox NicAlert™ Test Recommended by Tobacco Researchers
Nymox Enters Strategic Marketing Alliance with Cybear, a Member of the Andrx Corporation
Nymox Website Highly Rated in Web Exposure Report
Nymox Pharmaceutical Corp. to Hold Third Manhattan Alzheimer Disease Conference in November 2001
Nymox's AlzheimAlert™ Test Featured in Current Issues of Nursing and Radiology Periodicals
Nymox Pharmaceutical Corporation Makes Donation for the Victims of September 11, 2001
Nymox Appoints Dr. Paul A. Kraus as Clinical Consultant
Nymox's AlzheimAlert™ To Be Featured Topic on National Radio Show
Nymox NicAlert™ Test Slated for Large Second-Hand Smoke Study
Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports
Nymox E. Coli Treatment NXC 4720 Shows Encouraging Results
Nymox Enters into Korean Distribution Agreement for NicAlert™
Importance of Nymox AlzheimAlert™ Test Emphasized in Anti-Aging Medical Therapeutics Chapter
Nymox AlzheimAlert™ Used by Legal Experts in Forensic Cases
Nymox AlzheimAlert™ Protein "An Excellent Biomarker" for Alzheimer's Disease According to New Scientific Publication
Nymox Reports Successful AlzheimAlert™ Clinical Study Published in Neurology & Clinical Neurophysiology
Importance of Nymox AlzheimAlert™ Test Emphasized in New Publication in the Journal of Longevity
Nymox AlzheimAlert™ Test Featured in New Article in ADVANCE Laboratory Publication
Nymox Scientists Report Positive Clinical Trial Data for AlzheimAlert™ Test at World Congress of Neurology
Nymox Scientists Discover Important New Family of Therapeutic Compounds
Nymox Pharmaceutical Corporation Featured in The Wall Street Transcript
AMA Briefing Strongly Confirms the Importance of the Early Diagnosis of Alzheimer's Disease
Nymox AlzheimAlert™: "A Leap Forward in Early Detection"
New Medical Publication Links Nymox AlzheimAlert™ Protein with Alzheimer's Disease
Nymox Alzheimer Drug Programs Featured in Current Drug Discovery
Positive New Laboratory Studies for Nymox Alzheimer's Disease Drug Candidate
Nymox's AlzheimAlert™ Test Further Supported by New Medical Publications
Nymox Expands E. Coli Product Development
New Clinical Trial Publication Supports Nymox's AlzheimAlert™ Test
Nymox Adds Significant Value to Global Patent Holdings
Large New Community Study Proves Usefulness of Nymox's AlzheimAlert™ Test
Importance of Spherons in Alzheimer's Disease Highlighted by New Study
Nymox's NicAlert™ Measures Best Biomarker for Tobacco Use and Exposure
Nymox Announces Appointment of Scientific Consultants, Dr. Thomas Hudson and Dr. Joe Dylewski
Nymox Developing New Drug Candidates for the Treatment of Alzheimer's Disease
Experts Recommend Nymox's NicAlert™ Test
New Clinical Trial Data Supports Nymox's AlzheimAlert™ Test
New Study Confirms Again the Reliability and Efficacy of Nymox's AlzheimAlert™ Test
Prestigious Publication Confirms the Significance of Nymox's Alzheimer's Disease Marker
Nymox's AlzheimAlert™ Test Gaining Recognition and Wide Medical Acceptance
Nymox Announces E. Coli Collaboration with Prestigious Veterinary Institution
Nymox and Biophage to Co-Develop Antimicrobial Treatments
Nymox's E. Coli Inhibitor Effective in Independent Tests
Nymox Launches New Internet Presence
Nymox Management and Board of Directors Announce Share Purchase
Nymox Announces New Alzheimer Drug Screening Developments
Nymox to be Featured on American Medical Review
Nymox Presents AlzheimAlert™ Test at Annual Meeting of American Academy of Anti-Aging
Nymox Presents Positive Clinical Trial Data at Meeting of American Psychiatric Association
New Scientific Publication on Nymox Alzheimer Test
Nymox Alzheimer Test Recommended in Anti-Aging Medical News
Nymox Announces Launch of New AlzheimAlert™ Test
Nymox Appoints Robert Rush Ph.D. D.A.B.C.C. as New Clinical Laboratory Director for Alzheimer's Diagnostic Aid
Nymox Announces Marketing Launch with New Sales Force for Alzheimer Aid to Diagnosis
Nymox-Serex's Nicotine Test Shown to be Useful in Pediatric Second Hand Smoke Studies
Nymox Appoints Suzanna Levy Ph.D. as Clinical Laboratory Scientific Director for Alzheimer's Diagnostic Aid
Nymox's Product Portfolio Well-Positioned to Provide Diagnostic Testing for Aging Baby Boomers
World's First Direct Visualization of Bursting Spherons in Alzheimer's Disease Reported at Manhattan Alzheimer's Conference
Nymox Announces Positive Clinical Trial Result in 7C Gold Urinary Study in Alzheimer's Disease
New Confirmatory Findings on Spherons in Alzheimer's Disease Presented at International Congress of Neuropathology
New Publication Confirms Major Significance of Spherons in Alzheimer's Disease
First Urinary Diagnostic Aid by Nymox Proven to be Accurate by New Peer Reviewed Publication
Nymox Announces Agreement between Serex Inc. and Mizuho Medy Co. Ltd. in Japan
Nymox Announces Development of New Kit to Aid Alzheimer's Diagnosis
Nymox Announces New Member of the Board, Professor Walter P. von Wartburg
New Publication of Peer-Reviewed Study in Neurology Independently Verifies Nymox AD7C™ Test
Nymox Announces New Member of the Board, Michael R. Sonnenreich
Nymox's AD7C Test Found to be Highly Attractive and Useful in New Journal Publication
Nymox Completes Private Placement of $4.0 Million
Nymox Finalizes Acquisition of Majority Interest in Serex, Inc.
Two Recently Published Books Cite Value of Nymox's AD7C™ Test As Aid in Early Detection and Diagnosis of Alzheimer's Disease
Co-Founders of American Academy of Anti-Aging Medicine Laud Value of Nymox's Alzheimer's Developments
Diagnosing Memory Loss
Nymox Gaining Recognition as Scientific Advances Continue
Nymox Scientists Find Additional Evidence That Spherons Are Cause of Alzheimer's Disease
Nymox's New E. Coli Treatment Shows Promising Results
Nymox to Trade Exclusively on Nasdaq
Nymox Raises $12 Million in Financing Commitment
Nymox Pharmaceutical and Loyola Scientist Announce Link Between Statin Drugs and Lowered Rate of Alzheimer's Disease
Studies Validate New Nymox Alzheimer's Test; Nymox Reports Successful Completion of Initial Key Validation Studies for its New "7C Gold" Alzheimer's Disease Test
Clinical Laboratory News Terms Nymox's AD7C™ Test
Clinical Trials Confirms Accuracy of Nymox's AD7C™ Alzheimer Test, According to Paper Presented at American Assn. for Clinical Chemistry
Nymox Announces Breakthrough Development in Alzheimer Testing
Nymox Announces New Member of the Board Hans Black, M.D.
Nymox's Alzheimer Test Shown to have Expanded Clinical Usefulness
Human Testing Next Step for Nymox's Revolutionary Alzheimer Drugs
Nymox Announces Further Independent Clinical Study Data Verification of its AD7C™-NTP Alzheimer Testing Technology
Nymox Reports Positive Progress in Spheron Based Drugs for Alzheimer's Disease
Studies at International Symposium Support Nymox Alzheimer Test